LENZ Therapeutics (LENZ) Return on Capital Employed (2021 - 2026)
LENZ Therapeutics (LENZ) reported Return on Capital Employed of 44.93% for Q1 2026, down 1516.0% year-over-year from 3.17% in Q1 2025, and down 16.89% quarter-over-quarter from 38.44% in Q4 2025.
LENZ Therapeutics (LENZ) Return on Capital Employed (2021 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has 6 years of Return on Capital Employed data on file, last reported at 44.93% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 44.93%, down 1516.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 44.93% (down 1516.0% YoY), and the FY2025 annual result was 38.07%, up 619.0% from the prior year.
- Return on Capital Employed slipped to 44.93% in Q1 2026 per LENZ's latest filing, from 38.44% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 20.4% in Q1 2022 and troughed at 60.74% in Q1 2024.
- A 5-year average of 34.18% and a median of 31.15% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed slumped 3014 bps in 2024, then soared 3097 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 33.5% in 2022, then slumped by 44 bps to 48.35% in 2023, then soared by 42 bps to 28.01% in 2024, then plunged by 37 bps to 38.44% in 2025, then declined by 17 bps to 44.93% in 2026.
- Business Quant data shows LENZ's Return on Capital Employed at 44.93% in Q1 2026, 38.44% in Q4 2025, and 34.34% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -107.40% |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -50.43% |
| 10 | LENZ Therapeutics | 213.20 Mn | 213.20 Mn | 825,000.00 | -44.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.93% |
| Dec 31, 2025 | -38.44% |
| Sep 30, 2025 | -34.34% |
| Jun 30, 2025 | -31.15% |
| Mar 31, 2025 | -29.77% |
| Dec 31, 2024 | -28.01% |
| Sep 30, 2024 | -33.25% |
| Jun 30, 2024 | -37.39% |
| Mar 31, 2024 | -60.74% |
| Dec 31, 2023 | -48.35% |
| Sep 30, 2023 | -28.09% |
| Jun 30, 2023 | -28.12% |
| Mar 31, 2023 | -30.60% |
| Dec 31, 2022 | -33.50% |
| Sep 30, 2022 | -29.57% |
| Jun 30, 2022 | -24.36% |
| Mar 31, 2022 | -20.40% |
| Dec 31, 2021 | -15.23% |
| Sep 30, 2021 | -12.76% |